EGFR and non-small cell lung carcinoma: As a whole, although durvalumab has revealed a distinct advantage compared to chemotherapy in ATLANTIC trial, ICIs haven’t achieved a desired effect in treatment of EGFR-mutant NSCLC, neither first- nor second-setting.